The patent covers engineered meganucleases with altered DNA-cleavage specificity as well as modified DNA-binding affinity and/or modified dimerization properties.

Precision’s proprietary directed nuclease editor (DNE) technology facilitates to produce genome editing enzymes that can regulate, insert, remove and modify essentially any gene in mammalian or plant cells.

Precision BioSciences Scientific Development VP Derek Jantz said they look forward to develop and commercialize needed new technologies and products stemming from their proprietary DNE technology.